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Background: The use of monoclonal antibodies in combi-
nation with chemotherapy for the treatment of lymphoma
may improve efﬁcacy by utilizing distinct mechanisms of
tumor kill while minimizing overlapping toxicity. Bend-
amustine, a bifunctional alkylating agent, has been usedwith
Rituximab in indolent non-Hodgkin lymphomas, chronic
lymphocytic leukemia, and more recently for the treatment
relapsed and refractory diffuse large B-cell lymphomas
(DLBCL).
Brentuximab, a monoclonal antibody targeting CD30, is
approved for refractory and relapsed anaplastic large cell lym-
phoma, Hodgkin lymphoma relapsed after autologous stem cell
transplant and may have efﬁcacy in the treatment of DLBCL
which have been shown to express CD30 in 14-25% of cases.
We report the Mount Sinai Hospital experience using
bendamustine and brentuximab (BB) in the treatment of
relapsed-refractory lymphomas and its utility as a bridge to
transplant.
Methods: Retrospective analysis of the tolerability and out-
comes for patients receiving BB between 2013 and 2014 as
part of quality assurance review.
Results: Seven patients (1 female) were identiﬁed with a
median age of 39 (range 34-70). Diagnoses included Hodgkin
lymphoma (4), primary mediastinal B-cell lymphoma (1),
DLCBL (1), and peripheral T-cell enteropathy associated type
II lymphoma (1). Median time between initial diagnosis
and BB was 19 months (range 12-175 months). Patients
received a mean of 4.1 prior lines of therapy (range 2-9)
including allogeneic transplantation (1) and autologous
transplantation (4).
All patients received 90 mg/m2 of bendamustine and 1.8
mg/kg of brentuximab approximately every 3 weeks for a
mean of 2.71 cycles. Two patients developed sepsis and
fungal pneumonia, respectively. Of 6 patients evaluable for
response, 4 had partial response, 1 hadmixed response and 1
had PR after 2 cycles, then received a stem cell boost/DLI but
ultimately died from progression of disease (POD). 2 other
patients received allogeneic stem transplants and 3 patients
are awaiting transplantation.
Conclusion: BB in our heterogeneous and heavily pre-
treated population has been well tolerated, has provided
disease control, and has enabled patients to be bridged to
transplant, both allogeneic and autologous.Table.
Patient Diagnosis Age/Sex # of BB Cycles
1 Hodgkin Lymphoma 42/F 3
2 Primary Mediastinal
B cell lymphoma
34/M 3
3 Hodgkin Lymphoma 41/M 4
4 DLBCL 36/M 4
5 Hodgkin Lymphoma 36/M 2
6 Hodgkin Lymphoma 39/M 2
7 Peripheral T cell lymphoma,
enteropathy associated type 2
70/M 1453
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Introduction: HLA-haploidentical bone marrow trans-
plantation using posttransplant high-dose cyclophospha-
mide (Cy) has been increasingly performed, but relapse
remains a major problem. To test whether the addition of
busulfan to the conditioning regimen and the use of pe-
ripheral blood stem cells (PBSCs) instead of bone marrow
could reduce relapse, we conducted a multicenter phase II
study to evaluate the safety and efﬁcacy of posttransplant
Cy-based HLA-haploidentical peripheral blood stem cell
transplantation (PBSCT) after busulfan-containing reduced-
intensity conditioning.
Patients and Methods: This study started in May 2013 (Trial
identiﬁer: UMIN000010316). Patients aged from 15 to 65
with hematological malignancies who were planned for
HLA-haploidentical PBSCT were enrolled. The conditioning
regimen consisted of ﬂudarabine (30 mg/m2/day on days -6
to -2), Cy (14.5 mg/kg/day on days -6 and -5), busulfan (3.2Response Outcome
PR after 2 cycles Died POD
PR after 2 cycles Alive
s/p cord blood transplant
PR after 2 cycles Alive
Awaiting allogeneic transplant
PR after cycle 2, stable
disease after cycle 4
Alive
Awaiting allogeneic transplant
Mixed response after 2 cycles Alive
s/p cord blood transplant
Awaiting imaging s/p 2 cycles Alive
Awaiting autologous transplant
N/A Alive
Awaiting allogeneic transplant
Table 1
Patient demographics and baseline disease-related characteristics
Characteristic No GVHD
(n¼26)
GVHD
(n¼45)
Age at transplant (years) (median, IQR) 48 (32-57) 49 (34-56)
Gender (male) 13 (50%) 29 (64%)
Race
White 25 (96%) 34 (76%)
Black 1(4%) 10 (22%)
Other 0 (0%) 1 (2%)
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321S314mg/kg/day on days -3 and -2) and TBI (2 Gy on day -1). GVHD
prophylaxis consisted of Cy (50 mg/kg/day on days 3 and 4),
tacrolimus (days 5 to 180), and mycophenolate mofetil (days
5 to 60). Our primary endpoint was the incidence of non-
relapse mortality (NRM) at day 100. Secondary endpoints
included overall survival (OS), disease-free survival (DFS),
the incidence of engraftment, acute GVHD, and relapse.
Results: Median age was 48 (range 21-65) with 22 male and
9 female. Diagnosis of the patients included AML (n¼17),
ALL/LBL (n¼8), MDS/MPN (n¼4), and lymphoma (n¼2). The
majority (61.3%) of patients were not in remission and 13
patients (41.9%) had a history of prior allogeneic stem cell
transplantation (allo-SCT). Twenty-seven patients (87.1%)
engrafted with median neutrophil engraftment on 19 days
(range 15-27). The cumulative incidence of grades II-IV and
III-IV acute GVHD at day 100 was 22.6% (95% CI, 9.8-38.6%)
and 3.2% (95% CI, 0.2-14.4%), respectively. NRM at day 100
was 19.4% (95% CI, 7.7-34.9%). Cumulative incidence of
relapse at day 100 was 19.4% (95% CI, 7.7-35.0%). With a
median follow-up of 171 days, OS and DFS was 74.2% (95% CI,
55.0-86.2%) and 61.3% (95% CI, 42.0-75.8%), respectively, at
day 100. Subgroup analysis showed that patients who had a
history of prior allo-SCT had higher NRM (30.8% vs. 11.1%,
p¼0.07) and less lower OS (53.8% vs. 83.9%, p¼0.03) than
those in patients without a history of prior allo-SCT.
Conclusions: Our results suggest that posttransplant Cy
based HLA-haploidentical PBSCT after busulfan containing
reduced-intensity conditioning achieves stable donor
engraftment and low incidence of GVHD. NRM was accept-
able in the setting of the ﬁrst allo-SCT. Given the promising
results of GVHD and NRM, phase II study inmuch larger scale
are now under investigation.Ethnicity (Non-Hispanic) 26 (100%) 43 (96%)
Primary disease
ALL,AML,MDS 14 (54%) 24 (53%)
CML,CLL 4 (15%) 5 (11%)
Lymphoma 5 (19%) 11 (24%)
Other 3 (12%) 5 (11%)
Prior allogeneic HSCT 2 (8%) 3 (7%)
Donor
Match-related 6 (23%) 15 (33%)
Mismatch-related 7 (27%) 8 (18%)
Match-unrelated 6 (23%) 17 (38%)
Mismatch-unrelated 7 (27%) 5 (11%)
Cell source
Peripheral blood stem cells 19 (73%) 40 (89%)
Cord 7 (27%) 5 (11%)
Conditioning
Myeloablative 3 (12%) 7(16%)
Reduced intensity 23 (88%) 38 (84%)
GVHD prophylaxis
T-cell depletion (alemtuzumab) 12 (46%) 24 (53%)
Methotrexate + Tacrolimus 5 (19%) 13 (29%)
Mycophenolate + Tacrolimus 9(35%) 8 (18%)
Acute GVHD before endoscopy 16 (62%) 33 (73%)
Chronic GVHD before endoscopy 3 (12%) 6 (13%)
Table 2
Signs and symptoms (at endoscopy)
Characteristic No GVHD
(n¼26)
GVHD (n¼45)
Time from transplant (days)
(median, IQR)
188 (136-288) 160 (127-273)
Anorexia 10 (38%) 24 (53%)
Abdominal pain or cramping 11 (42%) 27 (60%)
Nausea or vomiting 16 (62%) 28 (62%)
Diarrhea 14 (54%) 39 (87%)
Weight loss (kg) (median, IQR) 8.3 (2.7-26.4) 13.7 (8.5-22.4)
Albumin change (median, IQR) -0.2 (-0.7-+0.4) -0.4 (-1.1-+ 0.3)
Platelet count (median, IQR) 98 (58-167) 118 (77-173)
Bilirubin (median, IQR) 0.6 (0.5-0.85) 0.7 (0.6-1.2)454
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Introduction: Gastrointestinal (GI) complications are com-
mon after allogeneic hematopoietic stem cell transplantation
(HSCT) and contribute to signiﬁcant morbidity andmortality.
Although the ﬁrst 100 days are typically considered the
“acute” period after a transplant, many GI events occur after
this time. These include “acute” GVHD (now reclassiﬁed as
late acute GVHD), classic chronic GVHD, and overlap syn-
drome, as well as infections, ulcers, drug reactions, andmore.
In order to shed light on the problem of late GI complications
after HSCT, we performed a single institution retrospective
study of HSCT patients requiring endoscopy after Day 100.
Methods: We identiﬁed 397 patients who underwent allo-
geneic HSCT between 1/1/05-12/31/10. Of these, 176 (44%)
had an endoscopic evaluation post-HSCT, including 79 with
endoscopies performed after Day 100. Eight of these were
performed for known conditions (e.g., follow up of previous
GI bleed, screening colonoscopy at 3 years), leaving 71 pa-
tients (18%) who had endoscopies for late GI symptoms. In
addition to reviewing these charts, biopsies were re-
reviewed by two pathologists, blinded to clinical ﬁndings, toensure uniform categorization in light of the NIH Consensus
Criteria (Biol Blood Marrow Transp 2005;11:945-955). In
addition to diagnosis, outcomes included overall survival
(OS) and treatment-related mortality (TRM).
Results: Of 71 patients with late GI complications requiring
endoscopy, 45 (63%) had GI GVHD [late acute: 39 (87%),
classic chronic: 1 (2%), overlap: 5 (11%)]. Of the 26 without
GVHD, the most common diagnoses were: infection (8: 6
CMV, 1 C diff, 1 unknown), gastritis/duodenitis (7), drugs
(one each on mycophenolate and valgancyclovir), local dis-
ease relapse (2), delayed motility (1), and unknown (6).
Baseline characteristics (Table 1) and signs and symptoms at
endoscopy (Table 2) were generally similar in both groups
with the exception of diarrhea which was more common in
patients with GVHD (87% vs. 54%, p¼0.01). While
multivariate logistic regression analysis showed apoptosis
score (1-4) was predictive of GVHD (OR¼2.35, 95% CI 1.18-
4.70), crypt destruction was predictive of need for TPN
(OR¼2.56, 95% CI 1.37-4.81). Patients with GVHD tended to
shorter overall survival (e.g., 2-year OS of 31% vs 50%) than
